World Journal of Urology最新文献

{"title":"Can preoperative transurethral catherization reduce the risk of urethral stricture after endoscopic treatment of the prostate?","authors":"Joren Vanthoor, Thomas R W Herrmann, Vincent De Coninck","doi":"10.1007/s00345-025-05474-y","DOIUrl":"https://doi.org/10.1007/s00345-025-05474-y","url":null,"abstract":"<p><p>Urethral strictures are a well-known complication following endoscopic treatment of benign prostatic hyperplasia (BPH). Although the exact cause remains unclear, repetitive instrument movement and pressure-induced ischemia are likely contributing factors. While the incidence seems lower after enucleation compared to transurethral resection of the prostate, it remains important to prevent this iatrogenic complication. A small randomized trial suggested a benefit from preoperative urethral dilatation, though findings were constrained by limited sample size and follow-up. Similarly, studies comparing resectoscope sizes have not yet demonstrated significant differences in stricture rates. Drawing parallels with ureteral stricture prevention, where prestenting with a ureteral catheter is commonly used, we hypothesize that preoperative transurethral catheterization may relax and dilate the urethra, potentially lowering the risk of stricture formation. Clinical observations support this: patients with preoperative indwelling catheters before endoscopic treatment of BPH often display a more compliant urethra during surgery. While mechanical irritation remains a theoretical concern of placing a catheter, the relaxing effect may outweigh potential harm, much like DJ-stent use in the ureter. A prospective study will be conducted within the EAU Endourology Consortium to evaluate this hypothesis, incorporating force-sensing dilators and standardized follow-up with uroflowmetry and cystoscopy at 3 and 6 months. If successful, preoperative catheterization may offer a simple, low-risk strategy to reduce urethral strictures in BPH surgery, particularly in patients with a narrow urethra.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"325"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Ruohui Huang and Liang Peng's letter to the editor for the article \"diagnostic performance of photodynamic diagnosis with oral 5-aminolevulinic acid for upper tract- and bladder urothelial carcinoma: a single-centre, retrospective analysis\".","authors":"Takeshi Sano, Takashi Yoshida, Takahiro Nakamoto, Hisanori Taniguchi, Masaaki Yanishi, Chisato Ohe, Hidefumi Kinoshita","doi":"10.1007/s00345-025-05687-1","DOIUrl":"https://doi.org/10.1007/s00345-025-05687-1","url":null,"abstract":"","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"326"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact on oncological outcomes of detrusor muscle absence in pTaHG urothelial carcinoma of the bladder? The end of the \"jump\" of the lamina propria layer myth.","authors":"Gabrielle Tissot, Pierre-Etienne Gabriel, Ulysse Dubuet, Sophie Régnier, Idir Ouzaid, Marco Moschini, Francesco Soria, David D'Andrea, Shahrokh F Shariat, Alexandra Budowski, Cédric Poyet, Mathieu Roumiguie, Mario Alvarez Maestro, Alberto Briganti, Wojciech Krajewski, Kees Hendricksen, Hans Veerman, Luca Afferi, Agostino Mattei, Carlo Di Bona, Stefania Zamboni, Claudio Simeone, Ronan Thenault, Gregory Verhoest, Jean-François Hermieu, Evanguelos Xylinas","doi":"10.1007/s00345-025-05669-3","DOIUrl":"https://doi.org/10.1007/s00345-025-05669-3","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the impact of detrusor muscle (DM) absence on oncological outcomes in patients with pTaHG within a large, multicenter cohort.</p><p><strong>Methods: </strong>This is a retrospective multicenter study based on a national database including 12 international expert centers. All patients who underwent transurethral resection of bladder tumor (TURBT) for a new diagnosis of pTaHG bladder cancer between January 2010 and December 2018 were included and divided into two groups according to the presence or absence of DM. Kaplan-Meier curves were used to illustrate survival outcomes, while Cox regression analyses were conducted to identify independent predictors of survival.</p><p><strong>Results: </strong>Overall, 418 patients had either pTaHG with DM (n = 365;87.3%) or without DM (n = 53;12.7%). After a median follow-up of 30 months, IQR [15;55], the 5-year RFS (40% vs. 50%; p = 0.2) and the 5-year PFS (75% vs. 86%; p = 0.2) were similar between both groups. Cox-regression analysis confirmed that absence of DM was not significantly associated with RFS (HR = 0.68; 95%CI= [0.41-1.15]; p = 0.15) and PFS (HR = 0.68; 95%CI= [0.27-1.69]; p = 0.40). Among 53 patients without DM, 29 (54.7%) underwent a second-look TURBT, with no impact on 5-year RFS (p = 0.1) and 5-year PFS (p = 0.07). Additionally, Cox-regression analysis confirmed that the absence of second-look was not associated with RFS (HR = 0.28; 95%CI= [0.09-0.93]; p = 0.04) and PFS (HR = 0.05; 95%CI= [0.00-0.89]; p = 0.04).</p><p><strong>Conclusion: </strong>Absence of DM on pathological specimen of pTaHG tumors had no impact on disease recurrence or progression occurrence, calling into question the need for routine second-look procedures for these patients.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"324"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of success rates between urethroplasty and perineal urethrostomy in the treatment of complex urethral strictures: a meta-analysis.","authors":"Xingming Zhao, Xingyu Li, Yuting Song, Qiang Guo, Jingqi Wang","doi":"10.1007/s00345-025-05679-1","DOIUrl":"https://doi.org/10.1007/s00345-025-05679-1","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to compare the effectiveness of urethroplasty and perineal urethrostomy (PU) in treating complex urethral strictures (CUS). CUS refers to strictures longer than 6 cm or those caused by prior surgeries, such as hypospadias or lichen sclerosus.</p><p><strong>Methods: </strong>A systematic literature search was conducted to identify relevant studies comparing urethroplasty and PU. The studies included were cohort designs that reported surgical success rates for both procedures. A total of 6 studies were included, involving 880 patients (624 undergoing urethroplasty and 256 undergoing PU). Data analysis was performed using Review Manager 5.3 software, and heterogeneity between studies was assessed using chi-square test (Cochran's Q) and the inconsistency index (I²).</p><p><strong>Results: </strong>The pooled analysis indicated no significant difference in the surgical success rates between the two groups (relative risk = 0.93, 95% CI: 0.84-1.03; p = 0.15). However, significant heterogeneity was observed (I² = 69%, p = 0.006), suggesting variability in the results across studies.</p><p><strong>Conclusion: </strong>Our study shows that PU and urethroplasty have similar success rates in treating CUS. Given the quality of the studies and the identified limitations, it is not possible to draw definitive conclusions. Meanwhile, the management of CUS, especially those involving lichen sclerosus or failed hypospadias repair, should be carried out in referral centers with specialized expertise to optimize patient outcomes.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"327"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flexible mini-percutaneous nephrolithotomy versus retrograde intra-renal surgery in the management of renal stones: a randomized controlled trial.","authors":"Ahmed Higazy, M Kandil, Ahmed Elshafei, M Esmat, A M Tawfeek","doi":"10.1007/s00345-025-05689-z","DOIUrl":"10.1007/s00345-025-05689-z","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the safety, efficacy, and cost-effectiveness of flexible mini-percutaneous nephrolithotomy (F-mPCNL) in managing nephrolithiasis compared to retrograde intrarenal surgery (RIRS).</p><p><strong>Methods: </strong>130 adult patients with renal stones (1.5-3 cm) were randomized to F-mPCNL or RIRS. The stone-free rate (SFR) was our primary outcome. Secondary outcomes were the operative time, fluoroscopy time, DJ stent insertion rate, auxiliary procedure needed, hospital stay, complications rate, total cost, and quality of life for both procedures.</p><p><strong>Results: </strong>out of 130 patients in our study, 125 were evaluated and completed the follow-up period. Preoperative data was similar in both groups including stone characteristics. F-mPCNL showed a better SFR of 95.1% compared to 77.8% in the RIRS group (p-value˂0.001), this was associated with less need for additional procedures. F-mPCNL was associated with a shorter operation time of 47.60 ± 14.54 min compared to 59.30 ± 20.10 min in the RIRS group (p-value˂0.001). F-mPCNL showed less radiational exposure and less need for DJ stent insertion than RIRS. The overall complication rate was comparable in both groups, postoperative pain, need for extra doses of analgesics, and hospital stay were higher in the F-mPCNL group. In our study, F-mPCNL was shown to be more cost-effective than RIRS.</p><p><strong>Conclusion: </strong>F-mPCNL showed a superior SFR in treating renal stones compared to RIRS in a single session, with less need for auxiliary procedures, shorter operative time, less radiational exposure, and better quality of life. However, it was associated with slightly more hospital stay and postoperative pain compared to RIRS.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"328"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The views of women and their physicians on decision-making for stress urinary incontinence.","authors":"Nienke J E Osse, Karine Gontijo-Santos Lima, Marian K Engberts, Hugo W F van Eijndhoven, Philippe D Violette, Rufus Cartwright, Marco H Blanker, Paul L P Brand","doi":"10.1007/s00345-025-05668-4","DOIUrl":"10.1007/s00345-025-05668-4","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment decisions for stress urinary incontinence (SUI) are preference sensitive, because the disease is non-lethal and there are multiple reasonable treatment options. However, little is known about patients' and physicians' preferred decision-making styles for SUI. To aid physicians in their counselling and decision-making in consultations for SUI, we studied patients' and physicians' preferred and perceived decision-making in medical specialist consultations for SUI.</p><p><strong>Methods: </strong>This mixed-methods study combined the validated control preference scale (CPS) and the CPS perception version, and semi-structured, in-depth interviews with both patients and physicians. This study took place in Canada, the United Kingdom and the Netherlands. Sixteen physicians from all three countries and seventeen women from the Netherlands and Canada were interviewed.</p><p><strong>Results: </strong>All women expressed a preference for being involved in the decision-making process, either by informative or shared decision-making (SDM) in the CPS, because they valued the autonomy to make their own choice regarding treatment for SUI and appreciated receiving information and advice from their doctor. Physicians also preferred an involved patient, but used medical expertise to steer towards their preferred treatment option. Physicians found SDM difficult to understand, expressing different interpretations.</p><p><strong>Conclusions: </strong>SDM is not a precise concept either for patients or physicians, with multiple interpretations. All patients with SUI want to be involved in the decision-making process, either by informative or by shared decision-making. Physicians both express the desire to involve patients in their decision making, but conversely to steer patients towards the decision that they feel suits them best.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"329"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reusable vs. single use cystoscope: economic & environmental assessment.","authors":"Said Ait Taleb, Nicole Francois, Badr Eddine Tehhani, Thomas Perez","doi":"10.1007/s00345-025-05705-2","DOIUrl":"https://doi.org/10.1007/s00345-025-05705-2","url":null,"abstract":"<p><strong>Purpose: </strong>To introduce a scalable methodology for assessing the economic and environmental impacts of reusable versus single-use devices, with a novel approach of processing reusable devices through low-temperature sterilization (LTS) (STERRAD®).</p><p><strong>Methods: </strong>The economic analysis used micro-costing techniques while carbon footprint was calculated with two different methods: \"UO Sté method\" derived from Deschavannes et al. (2021) and an ISO 14040/14044 Life Cycle Assessment (LCA) of the sterilization of the reusable device performed with OPENLCA v2.4.0 software and ELCD v3.2 free database. The uncertainty analysis was performed with a Monte Carlo analysis. These methods were applied to a case study from cystoscopes procedures performed (2023).</p><p><strong>Results: </strong>Our LCA study indicates an annual reduction of 582.4 kg CO₂ equivalent (-14.5%) in favor of reusable devices. Regarding the economic impact, more specific to our case study, the findings suggest an annual cost savings of €108,484, (-29%). It is important to note that the analysis is based on an \"in-house\" LCA model. Additionally, this study provides an objective comparison without considering logistical challenges, personnel requirements, or implementation costs of reusable devices. It does not substitute the collaborative medical and paramedical judgment of a urology department.</p><p><strong>Conclusions: </strong>LTS of reusable cystoscopes seems to have a significant decrease of the environmental footprint and economic impact.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"323"},"PeriodicalIF":2.8,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laser vs. bipolar prostate vaporization in bleeding-prone patients: a randomized trial and cutting-edge analysis.","authors":"Ahmed A Shorbagy, Mohammed Ismail, Youssef M Kotb, Mohamed Desouki, Mohamed Shabayek, Peter Hanna","doi":"10.1007/s00345-025-05692-4","DOIUrl":"10.1007/s00345-025-05692-4","url":null,"abstract":"<p><strong>Purpose: </strong>To compare effectiveness and safety of transurethral diode laser vaporization of prostate (diode LVP) versus bipolar transurethral vaporization of prostate (B-TUVP) in symptomatic benign prostatic hyperplasia (BPH) patients receiving oral anticoagulants/anti-platelet drugs.</p><p><strong>Patients and methods: </strong>All symptomatic prostate patients receiving oral anticoagulants/anti-platelet drugs are prospectively enrolled in the study between January 2023 to May 2024 in our institution. Of total 98 patients were randomized to B-TUVP (48 patients) or diode LVP (50 patients). The primary outcome is to compare B-TUVP with diode LVP regarding operative bleeding and postoperative hemoglobin drop. Secondary outcomes assess time of urinary irrigation, time of urethral catheter removal, length of hospital stays, and 6-month postoperative functional outcomes; IPSS, postoperative flow rate, and postvoid residual urine.</p><p><strong>Results: </strong>Baseline characteristics were similar in both groups. Diode LVP group had a significantly higher postoperative hemoglobin with a lower drop compared to B-TUVP group (p = 0.032, p = 0.007; respectively). The diode LVP group had a significantly reduced urinary irrigation duration compared to the B-TUVP group (p = 0.031). Also, diode LVP patients had early catheter removal compared to those in the B-TUVP group (p = 0.014). Additionally, the diode group had a notably reduced hospital stay duration compared to the B-TUVP group (p = 0.024). There were no significant differences between both groups regarding 6-month postoperative IPSS, Q max and PVRU.</p><p><strong>Conclusion: </strong>Diode LVP of the prostate is a safer alternative for treating BPH with fewer risks compared to B-TUVP especially in patients receiving anticoagulants. Nonetheless, both treatments yield similar 6-months functional outcomes.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"322"},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Youth matters: a systematic review of the molecular and clinical landscape of bladder cancer in young adults.","authors":"Ali Bourgi, Antoine Vincentelli, Emmanuel Rusch, Franck Bruyère","doi":"10.1007/s00345-025-05698-y","DOIUrl":"10.1007/s00345-025-05698-y","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is uncommon in individuals under the age of 45, and its clinical and molecular characteristics in this population differ significantly from those observed in older patients. This systematic review aims to evaluate recurrence, progression, survival outcomes, and molecular profiles of bladder cancer in young adults.</p><p><strong>Methods: </strong>A systematic search was conducted in MEDLINE, Embase, Scopus, and CENTRAL databases for studies published between 1998 and 2024. Eligible studies included patients aged ≤ 40 years and reported outcomes such as recurrence-free survival (RFS), progression, and overall survival (OS). A total of 18 studies were included. Risk of bias was assessed using the ROBINS-I tool, and pooled estimates were calculated using random-effects meta-analysis models.</p><p><strong>Results: </strong>Bladder cancer in young adults is predominantly non-muscle-invasive and low-grade, with high survival rates. Recurrence rates varied across studies, ranging from 0 to 35.9%, while disease progression was rare. Several studies reported 100% RFS and OS in pediatric and young adult populations. The molecular profile of tumors in younger patients differed from that of older adults, with lower rates of TP53 and FGFR3 mutations. Meta-analysis revealed favorable long-term outcomes, particularly in patients diagnosed at early stages.</p><p><strong>Conclusion: </strong>Bladder cancer in young adults presents a distinct clinical and molecular entity with excellent prognosis, minimal progression, and high survival. Despite this, recurrence remains a concern, highlighting the need for age-specific surveillance strategies and further research into molecular drivers of the disease in this age group.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"321"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of palliative transurethral resection of the prostate for lower urinary tract obstruction in patients with metastatic prostate cancer: a meta-analysis.","authors":"Reynier D Rodriguez Rosales, Jean-Pierre Trey Kanumuambidi, Arjun Venkatesh, Mohammed Al-Toubat, Nicole Murray, K C Balaji","doi":"10.1007/s00345-025-05664-8","DOIUrl":"https://doi.org/10.1007/s00345-025-05664-8","url":null,"abstract":"<p><strong>Purpose: </strong>This meta-analysis aims to assess the safety, efficacy, and outcomes of palliative transurethral resection of the prostate (TURP) for relieving urinary obstruction in patients with metastatic prostate cancer.</p><p><strong>Methods: </strong>A comprehensive literature search was performed across PubMed, MEDLINE, Scopus, Web of Science, and Google Scholar to identify studies published before August 2024. The included studies reported pre- and post-treatment outcomes in patients undergoing palliative TURP for urinary obstruction. Data were analyzed using Comprehensive Meta-Analysis and Review Manager software. Study quality was evaluated using the Newcastle Ottawa Scale, and bias was assessed using the Risk of Bias in Non-randomized Studies of Interventions tool.</p><p><strong>Results: </strong>Eight studies, including 3,080 patients with advanced prostate cancer, were included. Palliative TURP significantly reduced postvoid residual urine volume by a mean difference of 50.41 milliliters (95% confidence interval: 39.49-61.34, p < 0.00001) and improved the symptom score by 14.13 points (95% confidence interval: 10.03-18.23, p < 0.00001). However, no significant change was observed in the urinary flow rate (mean difference: 4.31 milliliters per second, p = 0.23). Reported complications included repeat TURP (23.4%), incontinence (13.9%), catheterization (10.8%), and TURP syndrome (2.7%).</p><p><strong>Conclusion: </strong>Palliative TURP effectively improves urinary symptoms and reduces urinary retention in patients with metastatic prostate cancer. While it offers symptomatic relief, the risk of postoperative complications should be carefully considered in treatment planning.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"320"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}